Eight weeks clears hepatitis C as well as twelve

The edition in brief

Hepatitis C: RESOLVE randomised 880 treatment-naive Indian adults without cirrhosis to 8 or 12 weeks of sofosbuvir-velpatasvir. Cure (SVR12) was 98.8% with 8 weeks and 99.0% with 12 weeks per protocol, a difference of 0.2% (−1.5 to 1.9), and the shorter course was also non-inferior by intention to treat. No drug-related serious adverse events occurred. Orforglipron: in ACHIEVE-4, 2,749 adults with type 2 diabetes and cardiovascular or kidney disease were randomised to this oral non-peptide GLP-1 receptor agonist or insulin glargine. Major cardiovascular events occurred in 4.2% against 5.0% (HR 0.84, 0.59–1.20), meeting non-inferiority; hypoglycaemia was a third as common but gastrointestinal effects affected 62%. Long-acting HIV therapy: in LATA, 476 suppressed adolescents in four African countries were switched to cabotegravir-rilpivirine injections every 8 weeks or kept on daily oral dolutegravir-based therapy. Confirmed viral rebound by week 96 was 0.9% against 6.4%, and the injections were superior. Conversational AI: in a single-centre feasibility study, 98 patients spoke to an AI system before an urgent primary care visit under physician supervision; no safety stops were needed, one hallucination was noted, and doctors found the summary helpful in three quarters of the cases they reviewed.